Stay updated on PEOPLE: Pembrolizumab in Low PD-L1 NSCLC Clinical Trial

Sign up to get notified when there's something new on the PEOPLE: Pembrolizumab in Low PD-L1 NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PEOPLE: Pembrolizumab in Low PD-L1 NSCLC Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The page now displays the ClinicalTrials.gov record for a phase II pembrolizumab study in advanced NSCLC, including its study design, eligibility criteria, outcomes, locations, and record history.
    Difference
    68%
    Check dated 2026-11-08T15:20:07.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0, while the page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T16:26:15.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    A banner announces NIH website updates and says that some NIH content may use “Super Intelligence” in place of “Artificial Intelligence” during the transition.
    Difference
    1%
    Check dated 2026-10-25T17:15:57.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision identifier changed from v3.7.1 to v3.7.2. The study record still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T22:11:58.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    The footer’s site revision label changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-11T22:09:37.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    The page previously showing a 403 Forbidden error now loads the full study record for NCT03447678, including the study overview, eligibility criteria, and locations. Additional metadata sections such as IPD sharing plans and relevant MeSH terms were added to enhance contextual information and searchability.
    Difference
    70%
    Check dated 2026-09-27T20:57:26.000Z thumbnail image

Stay in the know with updates to PEOPLE: Pembrolizumab in Low PD-L1 NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PEOPLE: Pembrolizumab in Low PD-L1 NSCLC Clinical Trial page.